January 14, 2019
Sound Pharmaceuticals begins with first patients in testing SPI-1005 in Phase 2 study
A Seattle-based privately held biopharmaceutical company, Sound Pharmaceuticals (SPI), said Monday it is advancing Phase 2 hearing loss clinical trial in Cystic Fibrosis, to study SPI-1005 in patients who are receiving intravenous (IV) tobramycin to treat acute pulmonary exacerbation.